Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.53 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 5/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.48 |
| ▸ | PIK3R1 | P27986 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL356845 | 0.85 | PIK3CD (0.51) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15812927 | 0.85 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15812924 | 0.85 | PIK3CD (0.60) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL21028559 | 0.82 | PIK3CD (0.59) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL16583284 | 0.82 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL356484 | 0.82 | PIK3CD (0.54) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL355538 | 0.80 | PIK3CD (0.57) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL20786770 | 0.80 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL20786769 | 0.80 | PIK3CD (0.55) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 | |
| SCHEMBL15242522 | 0.79 | PIK3CD (0.46) | PIK3CDPIK3CGPIK3CBPIK3CAPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8779131-B2 | 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-8779131-B2 | 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2014-07-15 | — | — | US | disclosed |
| US-20130231356-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2013-09-05 | — | — | US | disclosed |
| US-20130231356-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2013-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231356-A1 | QUINAZOLINONES AS INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | PIK3CD 1/4885PIK3CG 4/4885PIK3CB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.